Search
Search Results
##search.searchResults.foundPlural##
-
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4721Suppl. Files: 1281PDF: 1183Html: 332 -
THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
4438PDF: 2122HTML: 1977 -
MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT
942PDF: 525HTML: 1325 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
5033PDF: 1913HTML: 2896Untitled: 329 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3648PDF: 1493HTML: 2747 -
HEPATITIS C VIRUS INFECTION AND LYMPHOMA
1166PDF: 784HTML: 7888 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY. ITP and COVID19 infection and vaccination
1719PDF: 987HTML: 407 -
Refractory Immune Thrombocytopenic Purpura and Cytomegalovirus Infection: A Call for a Change in the Current Guidelines
4521PDF: 1298HTML: 2490Figure 1: 225 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4474PDF: 1625HTML: 486 -
Tenofovir as Rescue Therapy Following Clinical Failure to Lamivudine in Severe Acute Hepatitis B
2273PDF: 920HTML: 1658Figure 1: 608 -
THE ASSOCIATED FACTORS ON CYTOMEGALOVIRUS REACTIVATION OF CRITICALLY ILL IMMUNOCOMPETENT PATIENTS Cytomegalovirus Reactivation of Critically Ill Patients.
291PDF: 258HTML: 119 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
3107PDF: 1196HTML: 137 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
3063PDF: 1050HTML: 2126Cover letter: 228 -
Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era Antiviral and monoclonal Antibodies in Haematological Patients in the omicron era
1417PDF: 1041HTML: 112 -
Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy
1729PDF: 1050HTML: 243 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1693PDF: 1111HTML: 151 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
2812PDF: 1275HTML: 293 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2378PDF: 1700HTML: 746 -
Pathogen distribution, antimicrobial resistance, and mortality in febrile neutropenia among adults with hematological malignancies: a single-center cohort study
91PDF: 37Suppl. Files: 11Html: 25Html Suppl. Files: 6 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
1121PDF: 579HTML: 754 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2763PDF: 1751HTML: 2466Table1: 290 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4169PDF: 1232HTML: 480 -
Severe Acute Hepatitis B Treated with Entecavir
1753PDF: 933HTML: 2567Figure: 218Title page: 222disclosure: 146 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1847PDF: 872HTML: 934jdoe, table 2 infections CML .doc: 255jdoe, table 1 infections CML .doc: 233 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1363PDF: 587HTML: 23259 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
2139PDF: 899HTML: 270 -
FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator
3224PDF: 1115HTML: 3373 -
IMPLEMENTATION OF MICROELIMINATION STRATEGY IN ERADICATION OF CHRONIC HEPATITIS C INFECTION IN PATIENTS WITH HEMOPHILIA IN THE NORTHERN REGION OF SERBIA Microelimination Strategy of Chronic Hepatitis C Infection in patients with Hemophilia
1029PDF: 485HTML: 168







